我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
18
5 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
11
61.1%
尚未招募
5
27.8%
招募中
2
11.1%
暂无批准数据
- Real-world studies from Japan demonstrate that immune checkpoint inhibitors combined with platinum-based chemotherapy significantly improve overall survival in extensive-stage small cell lung cancer patients, with median survival extending from 9.7-9.8 months to 13.0 months. - The survival benefit was most pronounced in patients under 75 years of age and those with poor performance status (ECOG 2-3), while older patients showed limited benefit from immunotherapy addition. - These findings validate pivotal clinical trial results in diverse real-world populations, including patients often excluded from trials such as those with poor functional status and advanced age. - Treatment response rates improved significantly with immunotherapy, reaching 84.4% compared to 54.8% with chemotherapy alone, establishing immunotherapy combinations as effective standard care.
